Characteristic | No. of patients | % |
---|---|---|
Median age at diagnosis, year (range, IQR) | 73 (30-98, 58-80) | |
Gender | ||
Male | 128 | 71.5 |
Female | 51 | 28.5 |
Histology | ||
Carcinoma, unclassifiable | 83 | 46.4 |
Adenocarcinoma | 71 | 39.7 |
Squamous cell carcinoma | 6 | 3.4 |
Neuroendocrine carcinoma | 12 | 6.7 |
Others | 7 | 3.9 |
Histologic grade | ||
Poorly differentiated or Undifferentiated | 31 | 17.3 |
Unspecified | 148 | 82.7 |
Performance status | ||
0 | 19 | 10.6 |
1 | 67 | 37.4 |
2 | 44 | 24.6 |
3 | 27 | 15.1 |
4 | 22 | 12.3 |
Initial site at diagnosis | ||
Liver | 38 | 21.2 |
Lung | 23 | 12.8 |
Bone | 47 | 26.3 |
Central nervous system | 7 | 3.9 |
Peritoneum | 18 | 10.1 |
Lymph nodes | 43 | 24 |
Others | 3 | 1.7 |
Sites of disease involvement | ||
Liver | 80 | 44.7 |
Lung and pleural | 87 | 48.6 |
Bone | 74 | 41.3 |
Central nervous system | 14 | 7.8 |
Lymph nodes | 107 | 59.8 |
No. of metastatic organs | ||
1 | 40 | 22.3 |
2 | 52 | 29.1 |
> 2 | 87 | 48.6 |
Treatment | ||
Chemotherapy | 118 | 66.0 |
Radiotherapy | 52 | 29.1 |
Tyrosine kinase inhibitors | 2 | 1.1 |
Chemotherapy regimens | ||
Cisplatin-based | 89 | 75.4 |
5-FU-based | 51 | 43.2 |
Etoposide-based | 45 | 38.1 |
Gemcitabine-based | 17 | 14.4 |
Taxane-based | 13 | 11.0 |
Oxaliplatin-based | 11 | 9.3 |